Pravastatin for Hyperlipidaemia in HIV.
|ClinicalTrials.gov Identifier: NCT00227500|
Recruitment Status : Completed
First Posted : September 28, 2005
Last Update Posted : June 9, 2006
|Condition or disease||Intervention/treatment||Phase|
|HIV Infections Lipid Metabolism Glucose Metabolism Metabolic Abnormality Lipodystrophy Cardiovascular Disease||Drug: Pravastatin||Phase 4|
High serum cholesterol concentrations are commonly seen in HIV-infected patients treated with some protease inhibitor medications as part of long-term antiretroviral therapy for HIV. There is concern that these elevations in cholesterol may negatively impact on long-term risk of cardiovascular disease in this patient population. Pravastatin, a HMG-CoA reductase inhibitor, is commonly used to treat hypercholesterolaemia in the general population. We aim to examine the effect of 12 weeks therapy with 40mg pravastatin daily in conjunction with dietary advice in HIV-infected patients with elevated serum cholesterol on continued protease inhibitor therapy.
After 4 weeks of dietary advice, patients will be randomised to receive either pravastatin or placebo for 12 weeks. Assessments include fasting lipid and glycaemic parameters, measures of body composition and HIV disease, and surrogate markers for cardiovascular disease.
Although previous small studies of pravastatin in this field have been performed, none has done so in a randomised placebo controlled trial taking into account all the relevant measures.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Randomised, Double-Blind Study of Pravastatin for the Treatment of Hyperlipidaemia in Patients With HIV|
|Study Start Date :||July 2001|
|Estimated Study Completion Date :||October 2004|
- Between-group difference in time weighted change from baseline in fasting serum total cholesterol
- Includes: between-group difference in time weighted change: from wk 4 in fasting serum total cholesterol as well as from baseline in HDL-cholesterol and triglycerides; in total and regional body fat; in endothelial function
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00227500
|Australia, New South Wales|
|St. Vincents Hospital|
|Sydney, New South Wales, Australia, 2010|
|Principal Investigator:||Andrew D Carr, MD||National Centre in HIV Epidemiology and Clinical Research.|
|Study Director:||David A Cooper, MD||National Centre in HIV Epidemiology and Clinical Research.|